TrialScientific reports2022

Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease.

Manaf AlQahtani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.